Open AccessEFFICIENCY OF THE LOW-DOSE FORMS ESTROGEN-GESTAGEN DRUG TREATMENTTO WOMEN WITH COMPENSATED HYPOTHERIOSIS AND EUTHYROIDISM
Author(s) -
В А Громова,
В А Громова,
Н В Ворохобина,
Н В Ворохобина,
О.Ф. Малыгина,
О.Ф. Малыгина,
А. В. Кузнецова,
А. В. Кузнецова
Publication year - 2015
Publication title -
vestnik severo-zapadnogo gosudarstvennogo medicinskogo universiteta im. i.i. mečnikova
Language(s) - English
Resource type - Journals
eISSN - 2618-9704
pISSN - 2618-7116
DOI - 10.17816/mechnikov20157140-45
Subject(s) - medicine , estrogen , endocrinology , progestin , thyroid , hormone replacement therapy (female to male) , goiter , drug , thyroiditis , drospirenone , testosterone (patch) , pharmacology
The article presents research results of 61 perimenopausal and postmenopausal women with diffuse nodular nontoxic goiter and autoimmune thyroiditis, who in the 12 months received treatment low-dose combined estrogen-progestin drug, which includes a 1 mg 17-β estradiol and 2 mg drospirenone. The effect of hormone replacement therapy on coagulation and platelet hemostasis, lipid profile, pituitary-ovarian system, thyroid status were studied. Using of low-dose estrogen-progestin therapy does not worsen diffuse nodular nontoxic goiter and autoimmune thyroiditis flow, does not change the dose of thyroid medications and may be recommended for the treatment of menopausal symptoms in women with thyroid disease.